Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
Vaccine maker anticipates more inspections for remediation of Liverpool facility
February 20th, 2005
Chiron Corp. (CHIR) announced at a presentation at the 23rd annual J.P. Morgan Healthcare Conference that the company anticipates that the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool, England, manufacturing facility. The inspections will cover critical phases of the manufacture of Fluvirin influenza virus vaccine. With this regulatory process, the remediation effort may advance toward the restoration of the facility's license, as successive phases of manufacturing pass inspection by the MHRA....
Source: Medical Letter on the CDC & FDA (2005-02-20)
|
